What is EVOGEN-NIPT?

Learn about the genetic foundation of your baby’s health. Rapid advances in science and genetic technology have revolutionized the ability to diagnose hereditary diseases.
Now, you can have access to noninvasive prenatal testing (NIPT), which is a safe, accurate method to study the DNA of your baby during pregnancy.

«There was a revolution in the early diagnosis of fetal morbidity when NIPT appeared ...»

Mark A. Kurtser,
Academician of RAS, Doctor of Medical Sciences, General Director of the Group «MOTHER & CHILD».

ST. PETERSBURG INTERNATIONAL ECONOMIC FORUM, JUNE 2021.

Услуги EN
  • What is required to do this?

    Just a small quantity of blood is required from the mother that EVOGEN-NIPT can use to find a sufficient quantity of DNA to conduct an analysis.
  • When should this be done?

    EVOGEN-NIPT can be done starting in the 10th week of pregnancy!
  • What do we look for?

    EVOGEN-NIPT can pinpoint fetal chromosomal abnormalities that cause diseases like Down syndrome, Patau syndrome, and other medical conditions.
  • How does it work?

    EVOGEN-NIPT analyzes the blood from a pregnant woman. The baby’s fetal DNA is located right there. A baby’s fetal DNA is what is checked for the presence of chromosomal abnormalities, such as Down syndrome, Edwards syndrome, Patau syndrome, and various other syndromes.
    These diseases could cause health problems for your child.

Test options that can be paid for

  • EVOGEN-NIPT
    Basic
    Noninvasive prenatal DNA test on the fetus using the mother’s blood for the presence of trisomy 21, 18, 13, fetal sex determination.
  • EVOGEN-NIPT for twins
    Basic
    Noninvasive prenatal DNA test on the fetus using the mother’s blood for the presence of trisomy 21, 18, 13 during pregnancy with twins
  • EVOGEN-NIPT
    Standard
    Noninvasive prenatal DNA test on the fetus using the mother’s blood for the presence of trisomy 21, 18, 13; Х, Y chromosome aneuploidy, fetal sex determination.
  • EVOGEN-NIPT
    Extended
    Noninvasive prenatal DNA test on the fetus using the mother’s blood for the presence of trisomy 21, 18, 13; Х, Y chromosome aneuploidy; 60 microdeletions and duplications, fetal sex determination.
Public offer agreement